Propel Bio Management, LLC Avidity Biosciences, Inc. Transaction History
Propel Bio Management, LLC
- $172 Billion
- Q3 2024
A detailed history of Propel Bio Management, LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 178,500 shares of RNA stock, worth $7.72 Million. This represents 4.76% of its overall portfolio holdings.
Number of Shares
178,500
Previous 178,500
-0.0%
Holding current value
$7.72 Million
Previous $7.29 Billion
12.44%
% of portfolio
4.76%
Previous 4.73%
Shares
1 transactions
Others Institutions Holding RNA
# of Institutions
256Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$460 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$399 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$373 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$352 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$304 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.25B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...